Depo-Provera claims are quickly becoming a campaign category that plaintiff firms should monitor closely. The litigation centers on allegations that long-term use of Depo-Provera, a contraceptive injection containing medroxyprogesterone acetate,...
For mass tort and plaintiff firms, case acquisition is not just a marketing expense. It is a pipeline investment. Every paid lead source, referral partner, call campaign, co-counsel relationship, and digital intake channel should be evaluated by the same core...
The U.S. Judicial Panel on Multidistrict Litigation has created a new MDL for Boston Scientific spinal cord stimulator products liability cases, but the order is narrower than some plaintiffs requested. In MDL No. 3181, the Panel centralized Boston...
PFAS litigation continues to evolve quickly, and recent EPA actions are giving attorneys new regulatory benchmarks to evaluate water contamination claims. For law firms handling toxic exposure, environmental contamination, municipal water, or mass tort matters, the...
For many firms, the first instinct in mass tort marketing is to focus on ad volume: more impressions, more clicks, more calls, more form fills. That focus is understandable. Competitive torts move quickly, media costs can fluctuate, and firms often need claimant...
Mass tort marketing in 2026 is not just about finding the next big litigation. It is about understanding where claimant volume, court activity, advertising competition, and operational pressure are concentrating. The federal MDL system remains a major engine of mass...
